CTOs on the Move

Cigna Global Health

www.cignaglobalhealth.com

 
Everything we do is around our mission to help you improve your health, wellbeing and peace of mind. We have extensive experience in managing varied and unique clinical and service situations worldwide. Our vast experience, coupled with our expertise, enables us to provide high standards of healthcare coverage, regardless of where you are in the world. Cigna International by the numbers: • Our international health insurance plans give you access to a global network of over 1.5 million hospitals, clinics and doctors. • Our employees serve over 160 million customers in key markets around the globe. • Our Customer Care ...
  • Number of Employees: 5K-10K
  • Annual Revenue: > $1 Billion

Executives

Name Title Contact Details
Carmen Casagranda
Chief Information Officer Profile

Similar Companies

ARUP Laboratories

More than 65 academic medical centers use ARUP as their primary reference laboratory and ARUP also provides all laboratory services, including phlebotomy and support services, for the 490-bed University of Utah Hospitals and Clinics. ARUP's 1,700

Family Health Care Clinic

Family Health Care Clinic is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Prescott Valley, AZ. To find more information about Family Health Care Clinic, please visit www.familyhealthcareclinic.com

Protech Home Medical

Protech Home Medical is a rapidly growing leader in the provision of clinical respiratory equipment and service to patients.

SHI Consulting

SHI Consulting is a Toronto, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Relmada

Relmada Therapeutics (OTCQB: RLMD) is a clinical-stage, publicly traded specialty pharmaceutical company developing novel versions of proven drug products together with new chemical entities that potentially address areas of high unmet medical need in the treatment of chronic pain. Relmada has a diversified portfolio of four lead products at various stages of development including d-Methadone (REL-1017) its N-methyl-D-aspartate (NMDA) receptor antagonist for neuropathic pain; topical mepivacaine (REL-1021), its orphan drug designated topical formulation of the local anesthetic mepivacaine; oral buprenorphine (REL-1028) its oral dosage form of the opioid analgesic buprenorphine; and LevoCap ER (REL-1015), its abuse resistant, sustained release dosage form of the opioid analgesic levorphanol. Relmada`s product development efforts are guided by the internationally recognized scientific expertise of our research team. Relmada`s approach is expected to reduce clinical development risks and costs while potentially delivering valuable products in areas of high unmet medical needs.